Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...
Hosted on MSN16h
Biocurious: Hut Hut Hut! The growing list of ASX biotechs waiting for the FDA to call the start of playA large number of Australian biotechs are waiting for US FDA product approval – or are on the cusp of ... Read More The post ...
Twenty years ago, in 2004, Congress passed the Project BioShield Act, which established the Biomedical Advanced Research and ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
The Ghana Food and Drugs Authority (FDA) has spearheaded a joint initiative with National Regulatory Authorities (NRAs) in ...
1d
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback